All In Biotech

Drug Trial Radar · NCT02601157

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial

Last checked: Nov 19, 2026Latest source record: Jan 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,173 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,173

Actual

Start

Jan 18, 2016

Primary completion

Aug 14, 2021

Study completion Aug 14, 2022

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
B. Braun Korea Co., Ltd.
First posted
Nov 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems still needs to be established. Herein, we plan the HOST-coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial to compare single antiplatelet therapy (SAPT) after 3-month DAPT with 12-month DAPT in all-comers undergoing coronary intervention with third-generation DES with the thinnest struts. P2Y12 inhibitor treatment is added to aspirin during the 3-months period after the stenting, and this abbreviated duration of DAPT will be compared with conventional 1-year mandatory DAPT regimen in a 1:1 randomized stratification. Net adverse clinical events (NACEs), a composite of cardiac death, target vessel related myocardial infarction, clinically-drivent target lesion revascularization, definite or probable stent thrombosis and major bleeding is a primary endpoint for evaluating safety and efficacy of the difference of DAPT duration. 1-year target lesion failure (TLF) as a composite of cardiac death, target vessel related myocardial infarction and clinically driven target lesion revascularization will be identified as a secondary ischemic outcome. 1-year major bleeding events classified as BARC type 3 or 5 bleeding events will be identified as a secondary bleeding outcome. With this trial, you will be able to get clear insight on the behavior of newer DES platforms. Reference data for the shortened mandatory DAPT regimen will also be delineated in the selected patients, and it might be helpful to those who need it.

Conditions

  • Stable Angina
  • Unstable Angina
  • Non-ST Segment Elevation Myocardial Infarction

Interventions

  • 3-months DAPTDrug

    Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting

  • 1-year DAPTDrug

    Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. NACEs (net adverse clinical events)Time frame: post-stenting 12 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Busan Paik Hospital

    Busan, South Korea

  • Kosin University Gospel Hospital

    Busan, South Korea

  • SoonChunHyang University Cheonan Hospital

    Cheonan, South Korea

  • Chonnam National University Hospital

    Gwangju, South Korea

  • Gwangju Christian Hospital

    Gwangju, South Korea

  • Ewha Womans University Medical Center Mokdong Hospital

    Seoul, South Korea

  • Hallym University Kangdong Sacred Heart Hospital

    Seoul, South Korea

  • Kangnam Sacred Heart Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Kyung Hee University Hospital at Gangdong

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Ajou University Hospital

    Suwon, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.